Somatostatin Analogue Use to treat visual field loss in acromegaly newly diagnosed in pregnancy I.Frizelle, D.J.O'Halloran



Ospidéal Ollscoil Chorcaí Cork University Hospital

1. 11/40 gestation

Presenting with headacheunderwent CT brain.




Pituitary mass- MRI pituitary performed.


3. Visual field loss. Clinically acromegalic.

5. Pre:

And	utons. acettra	10/10/10-00-0015 10/10/10-00/00
		10 C
10 10 11 10 10		areas
		and the second
20 M M M M M M		3300000
	the second is a second s	
		· COSTANTING
	A REAL PROPERTY AND ADDRESS.	


Post:





4. Patient opted for medical therapy:
Octretide 100
micrograms TDS
commenced.

6. Further deterioration of



Improvement in visual field 2/52 after treatment start date.

7. Foetal growth on 50th centile throughout pregnancy
Elective caesarean at 34/40

visual fields requiring dose titration to 200 micrograms tds at 24/40.

8. Post partum labs Random GH 9.8 micrograms/L

Uncomplicated Baby girl 3.2Kg APGAR score 9 IGF-1 460 micrograms/L ()age- specific ref range

- **9**. *Points of interest*
- Fertility despite active undiagnosed disease.
- Successful treatment of visual field loss.
- Optimal obstetric outcome.

